Developer docs
API playgroundTry for free, no card

Search company profiles

Abingworth

Full company profile

uuid000071a

Namestring
Abingworth
Legal namestring
Abingworth LLP
Websiteurl
abingworth.com
Company typeenum
Private
Founded yearint
1987
Descriptiontext

Abingworth is a London-headquartered international life sciences investment group operating as a wholly owned subsidiary of The Carlyle Group following its August 2022 acquisition. The firm deploys capital across the full biopharmaceutical development lifecycle through a three-pillar platform: Seed & Early Stage venture investing (typical investment $15-$30m per company, 3-8 year hold, primarily US and Europe); Development Stage investing via its proprietary VIPEs (Venture Investments in Public Equities) approach; and Clinical Co-Development (CCD) partnerships with pharma and biotech companies for pivotal-stage biotherapeutics (minimum $30m per deal, often structured as hybrid equity plus development financing, 2-10 year hold). Since its first biotech investment in 1987, Abingworth has backed 190-201 life science companies across biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, gene therapies, and cell therapies, operating from offices in London, New York, and San Francisco with team coverage in Boston.

Revenue mechanics combine recurring management fees on committed fund capital with performance-based carried interest on exits. The firm has raised 15 dedicated life sciences funds, with the three most recent vehicles — Abingworth Bioventures 8 ($465m, 2020 vintage), Clinical Co-Development Fund 2 ($582m, 2021), and the Clinical Co-Development Co-Investment Fund ($356m, 2023) — representing the bulk of current investable capital. Notable CCD transactions include up to $210m for Gilead Sciences' Trodelvy ADC, $150m for Pathalys Pharma's upacicalcet, and $100m non-dilutive financing for CymaBay's seladelpar. The CCD strategy is operationally executed through Launch Therapeutics, Abingworth's dedicated clinical co-development vehicle.

The firm's reported outcomes include 36 product approvals since 2012, 75 IPOs, 53 M&A exits, and 17 CCD deals completed. Customer concentration is low across both LP capital (spread across 15 funds and multiple vintages) and portfolio companies (190-201 diversified positions). Recent deal flow into 2025-2026 spans co-led Series rounds in Cytospire, AdvanCell, R1 Therapeutics, and cAMPfield Therapeutics, plus major CCD collaborations with Gilead and Teva, indicating continued strong deal cadence under Carlyle ownership.

Short descriptiontext

Abingworth is a London-based life sciences investment group and wholly owned subsidiary of The Carlyle Group, managing 15 dedicated funds across seed, venture, public equity (VIPEs), and Clinical Co-Development strategies to back biotech entrepreneurs globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences venture capital, biotech venture investing, clinical co-development financing, healthcare private equity, biopharma investment funds
Industry1 code
PRIMARYFSANAAAJ
Venture Capital Fund-of-Funds / Multi-Manager Platforms
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Other Financial Vehicles525990
SIC code1 code
  • Investment Advice6282
Product category
Life Sciences Venture Capital
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Fund Management Fees
TypeSubscription Recurring
Description

Abingworth raises dedicated life sciences funds (15 funds to date including Bioventures 1-8, Clinical Co-Development 1 & 2, and CCD Co-Investment Fund) and earns management fees on assets under management. Most recent venture fund Abingworth Bioventures 8 raised $466 million; Clinical Co-Development Fund 2 raised $466 million; Clinical Co-Development Co-Investment Fund raised $356 million.

abingworth.com
2Carried Interest / Investment Returns
TypeManaged Services
Description

Earns carried interest (performance-based returns) from successful exits across the portfolio. Abingworth has achieved 36 product approvals since 2012, 75 IPOs, and 53 M&A exits, generating returns from successful biotech investments.

abingworth.com
3Clinical Co-Development Funding
TypeLicensing Royalties
Description

Provides structured development financing (minimum $30m per company, often combined with equity in hybrid financing solutions) to pharmaceutical and biotech companies for pivotal-stage biotherapeutics, seeking accelerated return through monetisation.

abingworth.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Abingworth is a life sciences investment firm that manages 15 dedicated life sciences funds across three core strategies: Seed & Early Stage venture investing (typical investment $15-$30 million per company), Development Stage including the firm's pioneering VIPEs (Venture Investments in Public Equities), and Clinical Co-Development (minimum $30 million per company for pivotal-stage biotherapeutics). The firm invests in biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, gene therapies, cell therapies, and platform technologies from offices in London, New York, and San Francisco, deploying both venture capital and structured hybrid financing solutions to biotech entrepreneurs on both sides of the Atlantic.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 36 product approvals since 2012
+5 more records
Product overview1 text field

Abingworth is a life sciences investment firm (now part of The Carlyle Group since August 2022) that operates a multi-pronged investment platform rather than a single product. Its core offering consists of approximately 15 dedicated life sciences and healthcare funds organized around three broad strategic pillars: Seed & Early Stage venture investing (exemplified by Abingworth Bioventures VI, VII, and VIII, the latest being ABV 8 which raised $466 million in 2020); Development Stage investing including the firm's pioneering VIPEs (Venture Investments in Public Equities) approach; and Clinical Co-Development (exemplified by CCD 1 launched in 2016, CCD 2 raised in 2021, and the CCD-CIF raised in 2023 at $356 million), which partners with pharmaceutical and biotech companies to fund pivotal-stage clinical trials. Across these strategies, Abingworth invests in biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, gene therapies, cell therapies, specialty pharma, and platform technologies, with typical venture investment sizes of $15-$30 million and minimum $30 million for clinical co-development deals. Abingworth has invested in over 190 life science companies since its founding and operates from offices in London, New York, and San Francisco.

Product and service6 records
1Abingworth Bioventures 8 (ABV 8)
CategoryVenture Fund
Description

Abingworth's most recent venture fund, vintage 2020, with $466 million dedicated to seed and early-stage life sciences investments across the US and Europe. Holds 16 portfolio companies. Typical investment size $15-$30 million per company with a 3-8 year holding period.

2Clinical Co-Development 2 (CCD 2)
CategoryClinical Co-Development Fund
Description

Pivotal-stage biotherapeutics financing fund raised in 2021 with $582 million, designed to partner with pharmaceutical and biotech companies to help develop effective new drugs and deliver them to patients in an accelerated manner through hybrid equity/financing solutions. Holds 4 portfolio companies.

3Clinical Co-Development Co-Investment Fund (CCD-CIF)
CategoryClinical Co-Development Fund
Description

Pivotal-stage biotherapeutics co-investment fund raised in 2023 with $356 million, investing alongside the flagship CCD 2 vehicle. Holds 3 portfolio companies and is actively investing in late-stage biotherapeutics.

4Clinical Co-Development 1 (CCD 1)
CategoryClinical Co-Development Fund
Description

Abingworth's first Clinical Co-Development fund launched in 2016, pioneering a new approach to partnering with pharmaceutical and biotech companies to fund expensive clinical trials through hybrid financing structures. Holds 16 portfolio companies.

5Abingworth Bioventures VII (ABV 7)
CategoryVenture Fund
Description

Venture fund with $315 million for seed and early-stage life science investments, vintage 2017. Holds 23 portfolio companies across the US and Europe.

6Abingworth Bioventures VI (ABV VI)
CategoryVenture Fund
Description

Venture fund raised in 2012 for life sciences investments. Holds 25 portfolio companies, the largest among Abingworth's venture funds.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierMinorTypeOthersAnnounced on2026-05-01
Description

Sarah Shackelton, who joined Jeito Capital as Partner, Talent, previously worked at Oxford Science Enterprises and Abingworth, bringing expertise in building senior leadership teams for VC-backed life sciences companies.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-03-01
Description

Alebund Pharmaceuticals entered into a licensing and equity agreement with Abingworth-backed R1 Therapeutics, granting exclusive rights to develop, manufacture, and commercialize the kidney disease drug AP306 outside Greater China. The collaboration includes potential milestone payments of up to low triple-digit millions of US dollars and tiered royalties in low double-digit percentages.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Launch Therapeutics is Abingworth's strategic development partner for clinical co-development deals, including the Pathalys Pharma collaboration to advance upacicalcet and the Teva dual-action asthma rescue inhaler program. Launch Therapeutics is a key vehicle for Abingworth's CCD strategy.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-02-01
Description

Abingworth portfolio company AdvanCell entered into a strategic collaboration with Lilly to advance novel targeted alpha therapies for the treatment of cancer, announced in February 2025.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-09-01
Description

Clinical collaboration agreement established between Teva and Abingworth-backed Launch Therapeutics to accelerate development of dual-action asthma rescue inhaler (ICS-SABA/TEV-'248) respiratory program, with Abingworth entering a strategic development funding agreement.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Abingworth led $150 million secured product financing and equity for Pathalys Pharma to advance upacicalcet through pivotal Phase 3 studies, forming a strategic collaboration with Launch Therapeutics. Pathalys Pharma subsequently raised $105 million Series B Financing in August 2024.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-08-01
Description

Carlyle completed its acquisition of Abingworth in August 2022, expanding Carlyle's global healthcare franchise with Abingworth's leading life sciences investment expertise. As part of The Carlyle Group, Abingworth operates as its life sciences investment platform. Carlyle's then-CEO Harvey Schwartz noted the strategic value of Abingworth's life sciences franchise.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

One of the largest dedicated healthcare/life-sciences investment firms globally, investing across venture, growth, public equity, and structured finance stages. Directly comparable to Abingworth's multi-strategy life-sciences platform and similar transatlantic footprint.

TypeDirect peer
Description

Early-stage life-sciences venture firm building biotech companies from inception, with offices in Cambridge, MA and London. Closely comparable to Abingworth's seed/early-stage strategy and transatlantic biotech focus.

TypeDirect peer
Description

Healthcare and life-sciences focused venture and growth investor with biotech, medtech, and healthcare services strategies. Comparable multi-strategy life-sciences platform; recently co-led with Abingworth on AdvanCell Series C.

TypeDirect peer
Description

Dedicated life-sciences investment firm investing across public and private biotech stages. Comparable to Abingworth's Bioventures and VIPEs strategies; led the cAMPfield Series A in which Abingworth participated.

TypeDirect peer
Description

Early-stage life-sciences venture firm with offices in San Francisco and Boston focused on building biotech companies from inception. Comparable seed/early-stage biotech focus to Abingworth Bioventures.

TypeDirect peer
Description

Healthcare-focused venture firm with presence in US, Canada, and Europe investing across biotech, medtech, and healthcare services. Comparable early-to-growth biotech investing model.

TypeDirect peer
Description

Large early-stage life-sciences and technology venture firm focused on founding and seeding biotech companies. Comparable seed/early-stage biotech focus with strong track record of biotech venture creation.

TypeDirect peer
Description

Healthcare-focused investment firm with venture, growth, public equity, and structured financing strategies. Comparable multi-strategy life-sciences platform to Abingworth's Bioventures + CCD + VIPEs combination.

TypeDirect peer
Description

European life-sciences venture capital firm investing across biotech stages with offices in Netherlands and Germany. Closely comparable to Abingworth's European biotech focus; participated alongside Abingworth in cAMPfield Series A.

TypeDirect peer
Description

Healthcare-focused investment manager operating a crossover fund that invests in public and private biotech companies. Comparable to Abingworth's public/private crossover approach (VIPEs) and participated in cAMPfield Series A alongside Abingworth.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment199 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Abingworth

Life Sciences Venture Capitalabingworth.com

Abingworth is a London-based life sciences investment group and wholly owned subsidiary of The Carlyle Group, managing 15 dedicated funds across seed, venture, public equity (VIPEs), and Clinical Co-Development strategies to back biotech entrepreneurs globally.

What Abingworth does

Abingworth is a London-headquartered international life sciences investment group operating as a wholly owned subsidiary of The Carlyle Group following its August 2022 acquisition. The firm deploys capital across the full biopharmaceutical development lifecycle through a three-pillar platform: Seed & Early Stage venture investing (typical investment $15-$30m per company, 3-8 year hold, primarily US and Europe); Development Stage investing via its proprietary VIPEs (Venture Investments in Public Equities) approach; and Clinical Co-Development (CCD) partnerships with pharma and biotech companies for pivotal-stage biotherapeutics (minimum $30m per deal, often structured as hybrid equity plus development financing, 2-10 year hold). Since its first biotech investment in 1987, Abingworth has backed 190-201 life science companies across biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, gene therapies, and cell therapies, operating from offices in London, New York, and San Francisco with team coverage in Boston.

Revenue mechanics combine recurring management fees on committed fund capital with performance-based carried interest on exits. The firm has raised 15 dedicated life sciences funds, with the three most recent vehicles — Abingworth Bioventures 8 ($465m, 2020 vintage), Clinical Co-Development Fund 2 ($582m, 2021), and the Clinical Co-Development Co-Investment Fund ($356m, 2023) — representing the bulk of current investable capital. Notable CCD transactions include up to $210m for Gilead Sciences' Trodelvy ADC, $150m for Pathalys Pharma's upacicalcet, and $100m non-dilutive financing for CymaBay's seladelpar. The CCD strategy is operationally executed through Launch Therapeutics, Abingworth's dedicated clinical co-development vehicle.

The firm's reported outcomes include 36 product approvals since 2012, 75 IPOs, 53 M&A exits, and 17 CCD deals completed. Customer concentration is low across both LP capital (spread across 15 funds and multiple vintages) and portfolio companies (190-201 diversified positions). Recent deal flow into 2025-2026 spans co-led Series rounds in Cytospire, AdvanCell, R1 Therapeutics, and cAMPfield Therapeutics, plus major CCD collaborations with Gilead and Teva, indicating continued strong deal cadence under Carlyle ownership.

Abingworth firmographics

Firmographics
Name
Abingworth
Legal name
Abingworth LLP
Website
https://abingworth.com
Company type
Private
Founded year
1987
Operating status
Operating
Headcount range
11–50 employees
Short description
Abingworth is a London-based life sciences investment group and wholly owned subsidiary of The Carlyle Group, managing 15 dedicated funds across seed, venture, public equity (VIPEs), and Clinical Co-Development strategies to back biotech entrepreneurs globally.
Ownership category
akta.pro rank

Abingworth industry classification

Industry
Product category
Life Sciences Venture Capital
NAICS
Portfolio Management and Investment Advice (523940), Other Financial Vehicles (525990)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAJ
Venture Capital Fund-of-Funds / Multi-Manager Platforms

Keywords

  • Life sciences venture capital
  • Biotech venture investing
  • Clinical co-development financing
  • Healthcare private equity
  • Biopharma investment funds

Where Abingworth is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices4 records

Markets served

Abingworth business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Fund Management Fees: Abingworth raises dedicated life sciences funds (15 funds to date including Bioventures 1-8, Clinical Co-Development 1 & 2, and CCD Co-Investment Fund) and earns management fees on assets under management. Most recent venture fund Abingworth Bioventures 8 raised $466 million; Clinical Co-Development Fund 2 raised $466 million; Clinical Co-Development Co-Investment Fund raised $356 million.
  2. Carried Interest / Investment Returns: Earns carried interest (performance-based returns) from successful exits across the portfolio. Abingworth has achieved 36 product approvals since 2012, 75 IPOs, and 53 M&A exits, generating returns from successful biotech investments.
  3. Clinical Co-Development Funding: Provides structured development financing (minimum $30m per company, often combined with equity in hybrid financing solutions) to pharmaceutical and biotech companies for pivotal-stage biotherapeutics, seeking accelerated return through monetisation.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Abingworth product offering

Product offering

Core offering

Abingworth is a life sciences investment firm that manages 15 dedicated life sciences funds across three core strategies: Seed & Early Stage venture investing (typical investment $15-$30 million per company), Development Stage including the firm's pioneering VIPEs (Venture Investments in Public Equities), and Clinical Co-Development (minimum $30 million per company for pivotal-stage biotherapeutics). The firm invests in biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, gene therapies, cell therapies, and platform technologies from offices in London, New York, and San Francisco, deploying both venture capital and structured hybrid financing solutions to biotech entrepreneurs on both sides of the Atlantic.

Product overview

Abingworth is a life sciences investment firm (now part of The Carlyle Group since August 2022) that operates a multi-pronged investment platform rather than a single product. Its core offering consists of approximately 15 dedicated life sciences and healthcare funds organized around three broad strategic pillars: Seed & Early Stage venture investing (exemplified by Abingworth Bioventures VI, VII, and VIII, the latest being ABV 8 which raised $466 million in 2020); Development Stage investing including the firm's pioneering VIPEs (Venture Investments in Public Equities) approach; and Clinical Co-Development (exemplified by CCD 1 launched in 2016, CCD 2 raised in 2021, and the CCD-CIF raised in 2023 at $356 million), which partners with pharmaceutical and biotech companies to fund pivotal-stage clinical trials. Across these strategies, Abingworth invests in biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, gene therapies, cell therapies, specialty pharma, and platform technologies, with typical venture investment sizes of $15-$30 million and minimum $30 million for clinical co-development deals. Abingworth has invested in over 190 life science companies since its founding and operates from offices in London, New York, and San Francisco.

Differentiator

Problem solved

Functional benefit

Products and services

  • Abingworth Bioventures 8 (ABV 8) Abingworth's most recent venture fund, vintage 2020, with $466 million dedicated to seed and early-stage life sciences investments across the US and Europe. Holds 16 portfolio companies. Typical investment size $15-$30 million per company with a 3-8 year holding period.
  • Clinical Co-Development 2 (CCD 2) Pivotal-stage biotherapeutics financing fund raised in 2021 with $582 million, designed to partner with pharmaceutical and biotech companies to help develop effective new drugs and deliver them to patients in an accelerated manner through hybrid equity/financing solutions. Holds 4 portfolio companies.
  • Clinical Co-Development Co-Investment Fund (CCD-CIF) Pivotal-stage biotherapeutics co-investment fund raised in 2023 with $356 million, investing alongside the flagship CCD 2 vehicle. Holds 3 portfolio companies and is actively investing in late-stage biotherapeutics.
  • Clinical Co-Development 1 (CCD 1) Abingworth's first Clinical Co-Development fund launched in 2016, pioneering a new approach to partnering with pharmaceutical and biotech companies to fund expensive clinical trials through hybrid financing structures. Holds 16 portfolio companies.
  • Abingworth Bioventures VII (ABV 7) Venture fund with $315 million for seed and early-stage life science investments, vintage 2017. Holds 23 portfolio companies across the US and Europe.
  • Abingworth Bioventures VI (ABV VI) Venture fund raised in 2012 for life sciences investments. Holds 25 portfolio companies, the largest among Abingworth's venture funds.

Quantifiable outcome

  • 36 product approvals since 2012
  • +5 more outcomes

Companies that use Abingworth

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Abingworth technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Abingworth partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered minor, major and flagship.

  • Jeito CapitalminorOthers · 1 May 2026Sarah Shackelton, who joined Jeito Capital as Partner, Talent, previously worked at Oxford Science Enterprises and Abingworth, bringing expertise in building senior leadership teams for VC-backed life sciences companies.
  • Alebund PharmaceuticalsminorStrategic or Co-development Partner · 1 March 2026Alebund Pharmaceuticals entered into a licensing and equity agreement with Abingworth-backed R1 Therapeutics, granting exclusive rights to develop, manufacture, and commercialize the kidney disease drug AP306 outside Greater China. The collaboration includes potential milestone payments of up to low triple-digit millions of US dollars and tiered royalties in low double-digit percentages.
  • Launch TherapeuticsmajorStrategic or Co-development Partner · 1 January 2026Launch Therapeutics is Abingworth's strategic development partner for clinical co-development deals, including the Pathalys Pharma collaboration to advance upacicalcet and the Teva dual-action asthma rescue inhaler program. Launch Therapeutics is a key vehicle for Abingworth's CCD strategy.
  • Eli LillymajorStrategic or Co-development Partner · 1 February 2025Abingworth portfolio company AdvanCell entered into a strategic collaboration with Lilly to advance novel targeted alpha therapies for the treatment of cancer, announced in February 2025.
  • Teva PharmaceuticalmajorStrategic or Co-development Partner · 1 September 2024Clinical collaboration agreement established between Teva and Abingworth-backed Launch Therapeutics to accelerate development of dual-action asthma rescue inhaler (ICS-SABA/TEV-'248) respiratory program, with Abingworth entering a strategic development funding agreement.
  • Pathalys PharmamajorStrategic or Co-development Partner · 1 January 2023Abingworth led $150 million secured product financing and equity for Pathalys Pharma to advance upacicalcet through pivotal Phase 3 studies, forming a strategic collaboration with Launch Therapeutics. Pathalys Pharma subsequently raised $105 million Series B Financing in August 2024.
  • The Carlyle GroupflagshipStrategic or Co-development Partner · 1 August 2022Carlyle completed its acquisition of Abingworth in August 2022, expanding Carlyle's global healthcare franchise with Abingworth's leading life sciences investment expertise. As part of The Carlyle Group, Abingworth operates as its life sciences investment platform. Carlyle's then-CEO Harvey Schwartz noted the strategic value of Abingworth's life sciences franchise.

Scale indicators16 records

Recent moves6 records

Expansion highlights5 records

Abingworth competitors and assessment

Company assessment

Direct peers

  • OrbiMed: One of the largest dedicated healthcare/life-sciences investment firms globally, investing across venture, growth, public equity, and structured finance stages. Directly comparable to Abingworth's multi-strategy life-sciences platform and similar transatlantic footprint.
  • Atlas Venture: Early-stage life-sciences venture firm building biotech companies from inception, with offices in Cambridge, MA and London. Closely comparable to Abingworth's seed/early-stage strategy and transatlantic biotech focus.
  • SV Health Investors: Healthcare and life-sciences focused venture and growth investor with biotech, medtech, and healthcare services strategies. Comparable multi-strategy life-sciences platform; recently co-led with Abingworth on AdvanCell Series C.
  • Frazier Life Sciences: Dedicated life-sciences investment firm investing across public and private biotech stages. Comparable to Abingworth's Bioventures and VIPEs strategies; led the cAMPfield Series A in which Abingworth participated.
  • 5AM Ventures: Early-stage life-sciences venture firm with offices in San Francisco and Boston focused on building biotech companies from inception. Comparable seed/early-stage biotech focus to Abingworth Bioventures.
  • Versant Ventures: Healthcare-focused venture firm with presence in US, Canada, and Europe investing across biotech, medtech, and healthcare services. Comparable early-to-growth biotech investing model.
  • ARCH Venture Partners: Large early-stage life-sciences and technology venture firm focused on founding and seeding biotech companies. Comparable seed/early-stage biotech focus with strong track record of biotech venture creation.
  • Deerfield Management: Healthcare-focused investment firm with venture, growth, public equity, and structured financing strategies. Comparable multi-strategy life-sciences platform to Abingworth's Bioventures + CCD + VIPEs combination.
  • Forbion: European life-sciences venture capital firm investing across biotech stages with offices in Netherlands and Germany. Closely comparable to Abingworth's European biotech focus; participated alongside Abingworth in cAMPfield Series A.
  • RA Capital Management: Healthcare-focused investment manager operating a crossover fund that invests in public and private biotech companies. Comparable to Abingworth's public/private crossover approach (VIPEs) and participated in cAMPfield Series A alongside Abingworth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Abingworth social profiles

Digital presence

Abingworth financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Abingworth leadership team

Management profile

Number of profiles

Profiles10 records

Abingworth subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Abingworth funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Abingworth M&A and investment

M&A and investment

M&A

Investments199 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abingworth

What does Abingworth do?

Abingworth is a life sciences investment firm that manages 15 dedicated life sciences funds across three core strategies: Seed & Early Stage venture investing (typical investment $15-$30 million per company), Development Stage including the firm's pioneering VIPEs (Venture Investments in Public Equities), and Clinical Co-Development (minimum $30 million per company for pivotal-stage biotherapeutics). The firm invests in biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, gene therapies, cell therapies, and platform technologies from offices in London, New York, and San Francisco, deploying both venture capital and structured hybrid financing solutions to biotech entrepreneurs on both sides of the Atlantic.

Is Abingworth a public or private company?

Abingworth is a private company. It is classified as corporate owned and is currently operating.

When was Abingworth founded?

Abingworth was founded in 1987. It employs 11 to 50 people.

Where is Abingworth based?

Abingworth is headquartered in London, United Kingdom, in the Europe region.

How does Abingworth make money?

Three revenue lines are on record. Fund Management Fees are the primary driver. The others are carried Interest / Investment Returns and clinical Co-Development Funding.

Who are Abingworth's main competitors?

Direct peers on record are OrbiMed, Atlas Venture, SV Health Investors, Frazier Life Sciences, 5AM Ventures, Versant Ventures, ARCH Venture Partners, Deerfield Management, Forbion and RA Capital Management.

Does Abingworth have an API?

No public API is recorded for Abingworth.

What industry is Abingworth in?

Abingworth's product category is Life Sciences Venture Capital. Its primary akta.pro industry code is FSANAAAJ, Venture Capital Fund-of-Funds / Multi-Manager Platforms. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Clinical Trials ArenaR1 Therapeutics secures $80.5m to fund Phase IIb AP306 studyR1 Therapeutics expanded its Series A financing to $80.5m to advance AP306 in a Phase IIb trial for hyperphosphatemia in dialysis-dependent chronic kidney disease patients. The round includes Samsara BioCapital and expects top-line results in the first half of 2027.Venture Capital Access OnlineR1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemiaR1 Therapeutics expanded its Series A financing to $80.5 million, adding Samsara BioCapital to an existing syndicate. The funds will advance AP306, a pan phosphate transporter inhibitor in a global Phase 2b trial for hyperphosphatemia in dialysis patients, with topline data expected in H1 2027.BioSpaceR1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemiaR1 Therapeutics expanded its Series A financing to $80.5 million, adding Samsara BioCapital to an existing syndicate. The funds will advance AP306, a pan phosphate transporter inhibitor in a global Phase 2b trial for hyperphosphatemia in dialysis patients, with topline data expected in H1 2027.European BiotechnologyRedx raises $36M to fund Phase 2 Crohn’s disease trialRedx raised $36M in a Series A round, led by Abingworth, to fund its Phase 2 trial of gut-restricted ROCK inhibitor RXC008 for fibrostenotic Crohn's disease. The financing includes a $68M private placement, extending the combined company's cash runway to 2029. Redx aims to report Phase 2 topline data in the second half of 2028.BusinessCloud$125m financing to see Macclesfield’s Redx list on NasdaqRedx Pharma, a Macclesfield-based biotech, agreed a $125m financing deal to list on Nasdaq as Fibrx Therapeutics. The deal includes a $36m Series A led by Abingworth and a $68m private placement, with Sky Bioscience acquiring Redx. The combined company will fund operations through 2029 and key clinical milestones, including RXC008 Phase 2 data expected in H2 2028.BioSpaceAdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand Clinical and Commercial Manufacturing InfrastructureAdvanCell closed a $315 million Series D financing led by Ally Bridge Group and co-led by Alpha Wave, with participation from new investors including Bain Capital Life Sciences and Fidelity. Proceeds will advance ADVC001, a Lead-212 PSMA-targeted therapy for metastatic prostate cancer, toward Phase 3 development and expand its vertically integrated manufacturing infrastructure.The Pharma LetterAdvanCell raises $315 million to accelerate lead-212 radiopharma pipelineAdvanCell closed an oversubscribed $315 million Series D financing to advance its lead-212 radiopharma pipeline and expand manufacturing. The round was led by Ally Bridge Group and co-led by Alpha Wave, with participation from Bain Capital Life Sciences, Fidelity, T Rowe Price, and others.FinSMEsAdvanCell Closes US $315M in Series D FundingAdvanCell raised $315M in Series D funding led by Ally Bridge Group and Alpha Wave, with participation from Bain Capital Life Sciences, Fidelity, and others. The company will use the funds to advance its Lead-212 PSMA-targeted therapy ADVC001 toward Phase 3 and expand its manufacturing infrastructure.GenengnewsNovartis to Acquire Myricx Bio for Up to $1.5B, Adding Cancer-Fighting ADC Payload PlatformNovartis agreed to acquire Myricx Bio, a London-based ADC developer, for up to $1.5 billion, combining its NMTi payload platform with Novartis' oncology pipeline. The deal includes $1.1 billion upfront plus up to $400 million in milestones, with closing expected in the second half of this year.SWI swissinfo.chNovartis acquires British start-up Myricx BioNovartis agreed to pay $1.1 billion to acquire British start-up Myricx Bio, which develops antibody-drug conjugates for solid tumours. The deal includes up to CHF400 million in milestone payments. The acquisition is part of Novartis' oncology diversification strategy.